Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Full Editions
BIOCENTURY
BIOCENTURY INNOVATIONS
BIOCENTURY EXTRA
BIOCENTURY WEEK IN REVIEW
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
Future Leaders
NewsMakers
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
search
Previous
article
Back
to Feed
Next
article
Share
Text Size
A
A
A
Print
FDA extends review of Samsung Bioepis' trastuzumab biosimilar
By Sandi Wong | Nov 9, 2018 | 1:14 AM GMT
A Samsung Bioepis Co. Ltd. spokesperson told BioCentury that FDA extended by three months
Read the full
149
word article
User Sign In
Previous
article
Back
to Feed
Next
article
JavaScript is necessary to work with this application.